BLU-0588 free base · Synonyms: BLU 0588 · BLU0588

BLU0588 is an orally active, potent and selective PRKACA kinase inhibitor.

For research use only. Not for human or veterinary use.

Target PKA

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

BLU-0588 structure

CAS No.: 2810747-78-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 530.00	BP-02057-100mg	In stock	Get quote
250 mg	USD 902.00	BP-02057-250mg	In stock	Get quote
500 mg	USD 1,375.00	BP-02057-500mg	In stock	Get quote
1 g	Inquire	BP-02057-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research.

Biological activity

Identifiers

SMILES: O=C(C1=CN=C(C2=C3C(NC=C3)=NC=C2)C=C1)N[C@H]4[C@H](N5CCCC5)CC6=CC=CC=C64
InChIKey: YXSWSKFLTNJZEO-DNQXCXABSA-N

Specifications

MW (average): 423.5096
Formula: C₂₆H₂₅N₅O
CAS No.: 2810747-78-3
Physical state: Solid
Color: White to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 83.33 mg/mL

Documents

References

[1]. Stefanie S. Schalm, et al. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. Gastro Hep Advances. Volume 2, Issue 3, 2023, Pages 307-321.

Same research area

Search Cancer